Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 24Terminated 9Recruiting 4Withdrawn 2Unknown 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 13Lymphoid 11Myeloid 8Plasma cell 2

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1

Interventions

Dexamethasone 130Lenalidomide 82daratumumab 60Bortezomib 56carfilzomib 45Calcium Dobesilate 41pomalidomide 37Cyclophosphamide 31isatuximab 26belantamab mafodotin 23Specimen Handling 21Biopsy 21Magnetic Resonance Spectroscopy 18dexamethasone acetate 16dexamethasone 21-phosphate 16ixazomib 15auricularum 15fludarabine 13Melphalan 13iberdomide 11elotuzumab 11selinexor 10fludarabine phosphate 9X-Rays 8talquetamab 7venetoclax 6trametinib 6nirogacestat 6Whole-Body Irradiation 6Thalidomide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Stem Cell Transplantation × Plasma cell × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03346135 2025-12-05

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

City of Hope Medical Center

Phase 2 Active not recruiting
31 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡